Pelliciari DHS, Reis CRA, Bordini CA. Should anti-CGRP monoclonal antibodies always be the drug of first choice for migraine prophylaxis in Brazil? – a pharmacoeconomic study. Headache Med [Internet]. 2024 Aug. 15 [cited 2024 Oct. 16];15(Supplement):98. Available from: https://headachemedicine.com.br/index.php/hm/article/view/1230